TrialsgrambetaRCTs are beautiful

RENAAL

2001

Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan

In 1,513 patients with type 2 diabetes and nephropathy, losartan reduced the composite of creatinine doubling, ESRD or death compared with placebo.

Result

Primary endpoint: Doubling of serum creatinine, ESRD or death

16% relative risk reduction (p=0.02); ESRD alone reduced 28% (p=0.002).

Original publication
Subtopic
RAAS blockade
Design
Double-blind RCT, median 3.4-year follow-up
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Brenner BM, et al. N Engl J Med. 2001;345(12):861-869.doi 10.1056/NEJMoa011161

Discussion & critique

First registration of an ARB for diabetic nephropathy; underpins the KDIGO 1A recommendation for ARBs in T2DM with albuminuria.

Discussed in podcasts